Detalle Publicación

ARTÍCULO

Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021.

Autores: Kissling, E. (Autor de correspondencia); Hooiveld, M.; Sandonis Martín, V.; Martínez-Baz, I.; William, N.; Vilcu, A. M.; Mazagatos, C.; Domegan, L.; de Lusignan, S.; Meijer, A.; Machado, A.; Brytting, M.; Casado, I.; Murray, J. L.; Belhillil, S.; Larrauri, A.; O'Donnell, J.; Tsang, R.; de Lange, M.; Rodrigues, A. P.; Riess, M.; Castilla Catalán, Jesús; Hamilton, M.; Falchi, A.; Pozo, F.; Dunford, L.; Cogdale, J.; Jansen, T.; Guiomar, R.; Enkirch, T.; Burgui Alcaide, Cristina; Sigerson, D.; Blanchon, T.; Martínez Ochoa, E. M.; Connell, J.; Ellis, J.; van Gageldonk-Lafeber, R.; Kislaya, I.; Rose Angela, M. C.; Valenciano, M.
Título de la revista: EUROSURVEILLANCE
ISSN: 1560-7917
Volumen: 26
Número: 29
Páginas: 2100670
Fecha de publicación: 2021
Resumen:
We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ¿ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.
DOI: https://doi.org/10.2807/1560-7917.ES.2021.26.29.2100670
Impacto:
Google Scholar